Effects of Linagliptin on Left Ventricular Myocardial DYsfunction in Patients With Type 2 DiAbetes Mellitus and Concentric Left Ventricular Geometry

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 188 participants.

Also called NCT02851745

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 188 participants (enrolled count) (from the registry)
Sponsor
Heart Care Foundation (from the registry)
Registry
  • NCT NCT02851745
Main results
  • Effects of linagliptin on left ventricular DYsfunction in patients with type 2 DiAbetes and concentric left ventricular geometry: results of the DYDA 2 trial European journal of preventive cardiology, 2021-03-23 DOI, PubMed 33755143

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Italy (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02851745. Randomized; quadruple masking; primary purpose treatment. Start 2015-07 (registry gives no type); primary completion 2019-07-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effects of Linagliptin on Left Ventricular Myocardial DYsfunction in Patients With Type 2 DiAbetes Mellitus and Concentric Left Ventricular Geometry
Acronym
DYDA2
Condition
Diabetes Mellitus, Type 2
Condition
Left Ventricular Systolic Dysfunction
Intervention (Drug)
Linagliptin
Intervention (Drug)
Placebo
Lead sponsor
Heart Care Foundation (class: other)
Collaborator
Fondazione dell'Associazione Medici Diabetologi (class: not stated)

Record details

Record id
cardio:ct-nct02851745
Content hash
d7d911a47c843ec85465184701b71db80f2283aa702ef674214d259bb88ecdcd